LIFECORE BIOMEDICAL, INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of $2.32 million for the 3-month period ending 2015-03-01, per its 10-Q filed 2015-04-02.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2015-04-02
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-03-01 was $2.32M, a 36.83% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-11-30 was $1.78M, a 4.75% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-08-31 was $1.30M, a 47.43% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-05-25 was $2.56M, a 110.46% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was $10.58M, a 11.97% increase from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2013 was $9.45M, a 31.55% increase from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2012 was $7.18M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month |
|---|---|---|---|---|
| 2015-03-01 | $2.32M 10-Q · filed 2015-04-02 | $4.11M derived: sum of 2 quarters · filed 2015-04-02 | $5.41M 10-Q · filed 2015-04-02 | $7.96M derived: sum of 4 quarters · filed 2015-04-02 |
| 2014-11-30 | $1.78M 10-Q · filed 2015-01-09 | $3.09M 10-Q · filed 2015-01-09 | $5.64M derived: sum of 3 quarters · filed 2015-01-09 | $9.32M derived: sum of 4 quarters · filed 2015-04-02 |
| 2014-08-31 | $1.30M 10-Q · filed 2014-10-08 | $3.86M derived: sum of 2 quarters · filed 2014-10-08 | $7.54M derived: sum of 3 quarters · filed 2015-04-02 | $9.41M derived: sum of 4 quarters · filed 2015-04-02 |
| 2014-05-25 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $6.23M derived: sum of 2 quarters · filed 2015-04-02 | $8.11M derived: sum of 3 quarters · filed 2015-04-02 | $10.58M 10-K · filed 2014-08-01 |
| 2014-02-23 | $3.68M 10-Q · filed 2015-04-02 | $5.55M derived: sum of 2 quarters · filed 2015-04-02 | $8.03M 10-Q · filed 2015-04-02 | $9.24M derived: sum of 4 quarters · filed 2015-04-02 |
| 2013-11-24 | $1.87M 10-Q · filed 2015-01-09 | $4.35M 10-Q · filed 2015-01-09 | $5.56M derived: sum of 3 quarters · filed 2015-01-09 | $8.32M derived: sum of 4 quarters · filed 2015-01-09 |
| 2013-08-25 | $2.48M 10-Q · filed 2014-10-08 | $3.69M derived: sum of 2 quarters · filed 2014-10-08 | $6.44M derived: sum of 3 quarters · filed 2014-10-08 | $9.36M derived: sum of 4 quarters · filed 2014-10-08 |
| 2013-05-26 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $3.97M derived: sum of 2 quarters · filed 2014-08-01 | $6.89M derived: sum of 3 quarters · filed 2014-08-01 | $9.45M 10-K · filed 2014-08-01 |
| 2013-02-24 | $2.75M 10-Q · filed 2014-03-28 | $5.67M derived: sum of 2 quarters · filed 2014-03-28 | $8.24M 10-Q · filed 2014-03-28 | $15.46M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-11-25 | $2.92M 10-Q · filed 2014-01-03 | $5.48M 10-Q · filed 2014-01-03 | $12.71M derived: sum of 3 quarters · filed 2014-08-01 | $12.69M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-08-26 | $2.56M 10-Q · filed 2013-09-26 | $9.79M derived: sum of 2 quarters · filed 2014-08-01 | $9.77M derived: sum of 3 quarters · filed 2014-08-01 | $9.72M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-05-27 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $7.20M derived: sum of 2 quarters · filed 2014-08-01 | $7.16M derived: sum of 3 quarters · filed 2014-08-01 | $7.18M 10-K · filed 2014-08-01 |
| 2012-02-26 | -$20.00K 10-Q · filed 2013-04-04 | -$60.00K derived: sum of 2 quarters · filed 2013-04-04 | -$35.00K 10-Q · filed 2013-04-04 | |
| 2011-11-27 | -$40.00K 10-Q · filed 2013-01-04 | -$20.00K 10-Q · filed 2013-01-04 | ||
| 2011-08-28 | $20.00K 10-Q/A · filed 2013-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |